NITE GLOW INDUSTRIES INC. v. CENTRAL GARDEN & PET COMPANY

District Court, D. New Jersey·Decided June 1, 2020·No. 2:12-cv-04047·Unknown

Opinion

NOT FOR PUBLICATION

UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY

NITE GLOW INDUSTRIES, INC., I DID IT,

INC., and MARNI MARKELL HURWITZ,

Plaintiffs, Civil Action No. 12-4047 (KSH) (CLW)

v.

CENTRAL GARDEN & PET COMPANY and FOUR PAWS PET COMPANY, D/B/A FOUR OPINION PAWS PRODUCTS, LTD.,

Defendants.

I. Introduction Plaintiffs asserted in this case that plaintiff Marni Markell Hurwitz (“Markell”) invented an applicator for flea and tick medication for animals and presented it to defendants, subject to a confidentiality agreement (the “Agreement”), in hopes that defendants would license it from her and develop the product as they had with prior inventions she brought to them. Defendants’ representative expressed great enthusiasm, took her materials, including her prototype, drawings, and patent application, and had them sent to the appropriate person or entity within defendants for further development. The head of that team told Markell they were moving forward. But instead, defendants proceeded to steal her idea, develop their own product (called the Smart Shield applicator), and cut Markell out—something she found out when she discovered her product at defendants’ booth at a 2012 pet expo in Orlando. Defendants vigorously disputed this version of events and denied in full plaintiffs’ claims, which, by the time the case went to the jury, consisted of misappropriation, breach of contract, and patent infringement. After six years of hard-fought litigation culminated in a three-week trial featuring 17 witnesses and several hundred exhibits, a jury awarded plaintiffs $12,656,900, consisting of $825,450 as reasonable royalties for infringement of claim 1 of U.S. Patent No. 8,057,445 (the ’445 patent), $825,450 for breach of the Agreement, and $11,006,000 for misappropriation, plus prejudgment interest in an amount to be determined upon motion by plaintiffs. The parties

subsequently filed and briefed several post-trial motions, three of which were orally argued at length on March 19, 2019: (1) defendants’ motion to vacate the judgment and for judgment as a matter of law, a new trial, and/or remittitur (D.E. 400); (2) plaintiffs’ motion to amend the judgment (D.E. 401); and (3) plaintiffs’ motion to amend the judgment by awarding enhanced damages for willful infringement (D.E. 404). For the reasons set forth below, the Court rejects defendants’ challenges to the jury’s finding of liability on the misappropriation and breach of contract claims. However, because a legal error underpinned the verdict with respect to the patent infringement claim, judgment as a matter of law will be entered in defendants’ favor on that claim, and because the breach of contract

damages are duplicative of the misappropriation damages, the judgment will be modified. With respect to remedies, plaintiffs’ requests to add language to the judgement and for an elevated ongoing royalty are denied in view of the Court’s ruling on the patent infringement claim. The Court also declines to require assignment to plaintiffs of defendants’ design patents and utility patent application. Prejudgment and post-judgment interest will be awarded as set forth herein. Because plaintiffs’ motion seeking enhanced damages (D.E. 404) and their motion for attorneys’ fees and expenses (D.E. 405) are predicated on the success of the patent infringement claim, they will be denied.1 II. The Parties’ Motions

Defendants attack the verdict from essentially every angle: they challenge liability and damages on each count, on multiple grounds. Plaintiffs defend the verdict in its entirety, and seek additional relief on all claims. A. Defendants’ Motion for Judgment as a Matter of Law, Remittitur, or a New Trial (D.E. 400) Defendants have sought to modify the judgment with respect to both liability and damages (see D.E. 400-1, Defs.’ JMOL Moving Br.). As to liability on the misappropriation claim, they argue that the claim was barred by the economic loss doctrine and that plaintiffs offered insufficient evidence of novelty, confidentiality, and use. As to the contract claim, defendants contend that plaintiffs failed to establish non-performance, and, alternatively, that the Court erred in declining to allow the jury to consider whether defendants’ obligations ceased when the patent application was published. As to the patent infringement claim, defendants argue that there was insufficient evidence to support the finding of contributory infringement because plaintiffs offered no evidence to

show that defendants’ products meet the “rubber” limitation of 1 of the ’445 patent, properly

1 In December 2019, plaintiffs also filed an informal letter application seeking an emergency order assigning them U.S. Patent Application No. 14/821,554, which they have contended should be assigned as part of the remedy for defendants’ breach of contract. (See D.E. 401-1 at 11-14; D.E. 441.) The Court declined to grant that relief on an emergent basis. (D.E. 446, 447.) With respect to plaintiffs’ request in the same submission for further enhancement of infringement damages beyond what is requested in their post-trial motions (D.E. 401, 404), which was not presented as an emergent request, the Court deferred consideration to its ruling on those motions. In light of the Court’s ruling here, the request for enhanced damages is denied as moot. construed. They also challenge the sufficiency of the evidence of (i) infringement with respect to the Zodiac products sold in Canada, (ii) contributory infringement, based on the “prong” limitation of claim 1 of the ’445 patent, and (iii) willful infringement. Defendants further contend that the Court should hold that claim 1 of the ’445 patent is invalid as indefinite. Alternatively, defendants seek a new trial on patent infringement because, they contend, the jury

was allegedly allowed to resolve competing definitions of a claim term, the Court provided an incorrect response to a jury question, and the Court erred in admitting evidence that the U.S. Patent and Trademark Office rejected defendants’ utility patent application based on the ’445 patent. With respect to damages, defendants argue that the jury’s award was duplicative and must be modified to eliminate the duplication, or else the Court should order remittitur or a new trial. They also contend that the award for misappropriation is excessive, including because net profits, rather than net sales, were allegedly awarded and the Court did not require apportionment. Defendants also challenge the award for breach of contract on apportionment

and sufficiency grounds. Likewise, defendants argue that a new trial should be granted on patent damages for failure to apportion. B. Plaintiffs’ Motion to Alter or Amend the Judgment (D.E. 401) Plaintiffs have moved pursuant to Fed. R. Civ. P. 59(e) to alter or amend the judgment. They seek (1) amendment of the judgment language to incorporate language from the verdict sheet regarding contributory infringement, infringement under 35 U.S.C. § 271(f), and willful infringement; (2) award of an elevated ongoing royalty; (3) assignment to plaintiffs of three design patents and one utility patent application held by defendants; (4) prejudgment interest on the award for each claim; and (5) post-judgment interest on the entire award. C. Plaintiffs’ Motion for Enhanced Damages (D.E. 404) Plaintiffs have also separately moved for an award of enhanced damages under 35 U.S.C. § 284 and Halo Elecs., Inc. v. Pulse Elecs., Inc., 136 S. Ct. 1923 (2016).

Free access — add to your briefcase to read the full text and ask questions with AI

NITE GLOW INDUSTRIES INC. v. CENTRAL GARDEN & PET COMPANY, (D.N.J. 2020).

NITE GLOW INDUSTRIES INC. v. CENTRAL GARDEN & PET COMPANY (NITE GLOW INDUSTRIES INC. v. CENTRAL GARDEN & PET COMPANY) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Desert Palace, Inc. v. Costa
539 U.S. 90 (Supreme Court, 2003)
United Phosphorus, Ltd. v. Midland Fumigant, Inc.
205 F.3d 1219 (Tenth Circuit, 2000)
Cytologix Corp. v. Ventana Medical Systems, Inc.
424 F.3d 1168 (Federal Circuit, 2005)
William A. Graham Co. v. Haughey
646 F.3d 138 (Third Circuit, 2011)
ZF Meritor LLC v. Eaton Corporation
696 F.3d 254 (Third Circuit, 2012)
Biogen Idec, Inc. v. GlaxoSmithKline LLC
713 F.3d 1090 (Federal Circuit, 2013)
New Jersey Power & Light Co. v. Mabee
197 A.2d 194 (Supreme Court of New Jersey, 1964)
Litton Industries, Inc. v. IMO Industries, Inc.
982 A.2d 420 (Supreme Court of New Jersey, 2009)
Rova Farms Resort, Inc. v. Investors Insurance Co. of America
323 A.2d 495 (Supreme Court of New Jersey, 1974)
Saltiel v. GSI Consultants, Inc.
788 A.2d 268 (Supreme Court of New Jersey, 2002)
County of Essex v. First Union National Bank
891 A.2d 600 (Supreme Court of New Jersey, 2006)
Wheatly v. Sook Suh
525 A.2d 340 (New Jersey Superior Court App Division, 1987)
Condus v. Howard Savings Bank
999 F. Supp. 594 (D. New Jersey, 1998)
Borough of Princeton v. Bd. of Chosen Freeholders of Mercer Cty.
777 A.2d 19 (Supreme Court of New Jersey, 2001)
Ahlert v. Hasbro, Inc.
325 F. Supp. 2d 509 (D. New Jersey, 2004)